AlzeCure’s vision is to become the leading research company developing groundbreaking drugs for Alzheimer’s, pain and other serious diseases with high unmet medical need.
AlzeCure Pharma’s strategy is to develop a broad portfolio of symptomatic, disease-modifying and preventive drugs for Alzheimer’s, pain and other serious illnesses through work based on the following four guidelines:
- The right patient: Focusing on genetically, clinically and pathologically defined diseases to increase the ability of clinical effect.
- The right mechanism: The treatment acts on genetically associated signal pathways in Alzheimer’s disease and other indications.
- The right clinical testing: The clinical studies are based on validated biomarkers and preclinical methods with good translation to humans.
- The right treatment: Small-molecule drugs that penetrate the blood brain barrier (BBB) and which are designed for safe, efficacious long-term treatment.
AlzeCure is evaluating possibilities for future collaboration agreements and commercial licensing agreements with leading pharmaceutical companies that can contribute R&D, manufacturing, commercialization and geographical reach to enhance the value of the Company’s drug platforms and drug candidates.